FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

by | Jul 1, 2026 | Health

Spread the love
By carefully controlling the mix of stem and T cells, Orca‑T lowers the risk for graft-vs-host disease in adults with hematologic cancers.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments